Semaglutide vs. Dulaglutide: Real-World Effectiveness in New Type 2 Diabetes Management
Background
Type 2 diabetes is a progressive metabolic disorder characterized by high blood sugar, requiring effective long-term management to prevent severe complications like cardiovascular disease and neuropathy. GLP-1 receptor agonists such as semaglutide and dulaglutide are increasingly vital therapeutic options, often prescribed alongside lifestyle modifications like a hypocaloric diet. While both agents are known for their efficacy in glycemic control and weight management, comprehensive real-world comparative data on their specific effectiveness in newly diagnosed patients adhering to a hypocaloric diet remains less understood.